Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Ep... (461 +4.3% United Sta...)

Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin

Date:4/30/2008

461 +4.3%

United States 778 +44.6%

Other Countries 231 +32.0%

TOTAL 1,470 +27.3%

In the United States, sales of Plavix(R) (consolidated by Bristol Myers Squibb -- BMS) reached $1,142 million in the first quarter, versus $789 million in the first quarter of 2007 when the product was still affected by the presence of a generic version.

In Europe, net sales of Plavix(R) were up 4.3% at EURO 461 million, though sales are still being affected by Germany.

In addition, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recently issued a positive opinion recommending approval of the 300mg tablet of Plavix(R). This positive opinion from the CHMP must be ratified by the European Commission in the coming months before final approval.

In the Other Countries region, Plavix(R) reported a strong advance in sales of 32.0% to EURO 231 million, supported by the product's success in Japan (net sales of EURO 28 million, compared with EURO 4 million in the first quarter of 2007).

Worldwide presence of Aprovel(R)/ Avapro(R)/ Karvea(R)

EURO million Q1 2008 Change on a comparable basis

Europe 245 +8.4%

United States 119 +8.2%

Other Countries 108 +22.7%

TOTAL 472 +11.3%

First-quarter worldwide sales of Aprovel(R)/Avapro(R)/Karvea(R) were up 11.3% at EURO 472 million.

Net sales by business segment -- Human Vaccines

First-quarter consolidated net sales for the Human Vaccines division rose by 2.8% to EURO 548 million.

Menactra(R) was the main growth driver, with net sales up 48.1% at EURO 99 million.

Net sales of Adacel(TM) (adult and
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Tubbs Jones Introduces Resolution Encouraging STD Prevention
2. New electronic health records demonstration project encouraging step says ACP
3. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
4. Digirad Corporation Reports Financial Results for First-Quarter 2008
5. Essilors 2008 First-Quarter Report
6. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
9. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Abbott Hosts Conference Call for First-Quarter Earnings

Post Your Comments:

Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Ep...(461 +4.3% United Sta...),Health